153 related articles for article (PubMed ID: 11797510)
1. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
Franzius C; Bielack S; Flege S; Eckardt J; Sciuk J; Jürgens H; Schober O
Nuklearmedizin; 2001 Dec; 40(6):215-20. PubMed ID: 11797510
[TBL] [Abstract][Full Text] [Related]
2. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
[TBL] [Abstract][Full Text] [Related]
3. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
4. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
5. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients.
Berger M; Grignani G; Giostra A; Ferrari S; Ferraresi V; Tamburini A; Cefalo G; Carnevale-Schianca F; Vassallo E; Picci P; Pagano M; Aglietta M; Pellerito RE; Fagioli F
Ann Oncol; 2012 Jul; 23(7):1899-905. PubMed ID: 22104576
[TBL] [Abstract][Full Text] [Related]
6. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.
Loeb DM; Hobbs RF; Okoli A; Chen AR; Cho S; Srinivasan S; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2010 Dec; 116(23):5470-8. PubMed ID: 20715156
[TBL] [Abstract][Full Text] [Related]
7. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours.
Milner RJ; Dormehl I; Louw WK; Croft S
J S Afr Vet Assoc; 1998 Mar; 69(1):12-7. PubMed ID: 9646255
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Anderson PM; Wiseman GA; Erlandson L; Rodriguez V; Trotz B; Dubansky SA; Albritton K
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6895-900. PubMed ID: 16203780
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.
Loeb DM; Garrett-Mayer E; Hobbs RF; Prideaux AR; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2009 Jun; 115(11):2514-22. PubMed ID: 19338063
[TBL] [Abstract][Full Text] [Related]
10. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
11. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Bruland OS; Skretting A; Solheim OP; Aas M
Acta Oncol; 1996; 35(3):381-4. PubMed ID: 8679270
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
13. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Anderson PM; Subbiah V; Rohren E
Adv Exp Med Biol; 2014; 804():291-304. PubMed ID: 24924181
[TBL] [Abstract][Full Text] [Related]
14. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.
Senthamizhchelvan S; Hobbs RF; Song H; Frey EC; Zhang Z; Armour E; Wahl RL; Loeb DM; Sgouros G
J Nucl Med; 2012 Feb; 53(2):215-24. PubMed ID: 22251554
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study.
Fagioli F; Aglietta M; Tienghi A; Ferrari S; Brach del Prever A; Vassallo E; Palmero A; Biasin E; Bacci G; Picci P; Madon E
J Clin Oncol; 2002 Apr; 20(8):2150-6. PubMed ID: 11956277
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
18. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
[TBL] [Abstract][Full Text] [Related]
19. Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP).
Aas M; Moe L; Gamlem H; Skretting A; Ottesen N; Bruland OS
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3148s-3152s. PubMed ID: 10541356
[TBL] [Abstract][Full Text] [Related]
20. The role of radiotherapy in oseosarcoma.
Schwarz R; Bruland O; Cassoni A; Schomberg P; Bielack S
Cancer Treat Res; 2009; 152():147-64. PubMed ID: 20213389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
